Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (761-770 of 903) with videos related to

Pageof 91
Sort By:
Hematological Oncology|December 24, 2024
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic LeukemiaElena Bibikova, Sara Parsa, Muskan Floren, et al.
Haematologica|March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineWilliam Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Blood|December 7, 2013
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)Jennifer A Woyach, Engin Bojnik, Amy S Ruppert, et al.
Plos One|October 17, 2013
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to diseaseErin Hertlein, Kyle A Beckwith, Gerard Lozanski, et al.
Blood|March 12, 2014
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphomaIan W Flinn, Brad S Kahl, John P Leonard, et al.
Cancer Research|February 17, 2016
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib TreatmentAndrew Stiff, Prashant Trikha, Robert Wesolowski, et al.
Genome Research|March 12, 2021
DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemiaBrian Giacopelli, Min Wang, Ada Cleary, et al.
Transplantation|September 23, 2003
Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantationSteven Z Pavletic, R Gregory Bociek, James M Foran, et al.
The Journal of Clinical Investigation|July 18, 2017
Ibrutinib treatment improves T cell number and function in CLL patientsMeixiao Long, Kyle Beckwith, Priscilla Do, et al.
Pageof 91

Showing results (761-770 of 903) with videos related to

Sort By:
Pageof 91
Hematological Oncology|December 24, 2024
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic LeukemiaElena Bibikova, Sara Parsa, Muskan Floren, et al.
Haematologica|March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a <i>KMT2A</i> partial tandem duplication targeted therapy: results of phase 1 study NCI 8485Alice S Mims, Anjali Mishra, Shelley Orwick, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineWilliam Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Blood|December 7, 2013
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)Jennifer A Woyach, Engin Bojnik, Amy S Ruppert, et al.
Plos One|October 17, 2013
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to diseaseErin Hertlein, Kyle A Beckwith, Gerard Lozanski, et al.
Blood|March 12, 2014
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphomaIan W Flinn, Brad S Kahl, John P Leonard, et al.
Cancer Research|February 17, 2016
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib TreatmentAndrew Stiff, Prashant Trikha, Robert Wesolowski, et al.
Genome Research|March 12, 2021
DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemiaBrian Giacopelli, Min Wang, Ada Cleary, et al.
Transplantation|September 23, 2003
Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantationSteven Z Pavletic, R Gregory Bociek, James M Foran, et al.
The Journal of Clinical Investigation|July 18, 2017
Ibrutinib treatment improves T cell number and function in CLL patientsMeixiao Long, Kyle Beckwith, Priscilla Do, et al.
Pageof 91